VENITIUS NUNEZ: Open Payments
NPI 1407973035 · CAMDEN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,190 in 217 payments from 12 companies in 2025. Trend: 2023 $1,264 · 2024 $2,081 · 2025 $3,190
Food & beverage: $3,085Education: $105
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $513 |
| ABBVIE INC. | 42 | $489 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $433 |
| Alkermes, Inc. | 18 | $350 |
| Neurocrine BioSciences, Inc. | 27 | $314 |
| E.R. Squibb & Sons, L.L.C. | 23 | $298 |
| Otsuka America Pharmaceutical, Inc. | 16 | $281 |
| Vanda Pharmaceuticals Inc. | 12 | $214 |
| Janssen Pharmaceuticals, Inc | 10 | $153 |
| Axsome Therapeutics, Inc. | 5 | $73 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, ARISTADA, COBENFY, AUSTEDO XR, FANAPT, REXULTI.
Industry payments across NJ — which companies pay providers there.
